First-in-Human Experience With Ultra-Low Temperature Cryoablation for Monomorphic Ventricular Tachycardia
Language English Country United States Media print-electronic
Document type Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
36752466
DOI
10.1016/j.jacep.2022.11.017
PII: S2405-500X(22)01049-0
Knihovny.cz E-resources
- Keywords
- ultra-low temperature cryoablation, ventricular tachycardia ablation,
- MeSH
- Endocardium MeSH
- Tachycardia, Ventricular * MeSH
- Cryosurgery * adverse effects MeSH
- Humans MeSH
- Heart Ventricles MeSH
- Temperature MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Ultra-low temperature cryoablation (ULTC) using near-critical nitrogen (-196ºC) has been shown to produce durable, contiguous, transmural lesions in ventricles of animal models. This report summarizes acute experience with ULTC in the first-ever 13 patients with recurrent monomorphic ventricular tachycardias (VTs) of both ischemic cardiomyopathy and nonischemic etiologies enrolled in the CryoCure-VT (Cryoablation for Monomorphic Ventricular Tachycardia; NCT04893317) clinical trial. After an average of 9.6 ± 4.6 endocardial ULTC lesions per patient, no clinical ventricular tachycardias were inducible in 91% of patients. Two procedure-related serious adverse events recorded in 2 patients resolved post-procedurally without clinical sequelae. Further investigation of both acute and chronic outcomes is warranted and ongoing.
Adagio Medical Inc Laguna Hills California USA
Cardiovascular Center OLV Hospital Aalst Belgium
McGill University Montreal Quebec Canada
Mount Sinai Hospital New York New York USA
Na Homolce Hospital Prague Czech Republic
References provided by Crossref.org
ClinicalTrials.gov
NCT04893317
